The collaboration aims to drive long-term brain monitoring and neurostimulation innovations into clinical applications....
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation ...
With a strategic separation, BD is creating a pure-play MedTech leader and a focused Life Sciences and Diagnostics entity, driving enhanced investment, innovation, and market impact....
The collaboration aims to promote virtual reality solutions for enhancing senior care and well-being....
Simultaneous approval of AI solutions for diagnosing sleep disorders and digital therapeutics for insomnia...
Strategic move aims to accelerate advancements in cancer detection and drug development....
World’s first pin-less, image-less solution for precise acetabular cup positioning in anterior hip arthroplasty....
Asia-Pacific region houses some of Galderma’s fastest growing markets, where sales have fueled a strong performance. There have been multiple successes in the region in 2024 for the Swiss pharmaceutical firm, with a number of important product launches, such as Restylane VOLYME in China, Restylane EYELIGHT in Korea and Alastin in Australia. More recently, Relfydess (RelabotulinumtoxinA) was approved in Australia and Sculptra - which celebrated its 25th launch anniversary this year - was approved...
The enhanced system now supports multiple languages, improving accessibility for global drug screening operations....
The partnership aims to enhance Memory Lane Games' reach in the senior care community, leveraging Slatton’s influence to promote cognitive health and engagement solutions....
